Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
United Therapeutics Corp. (UTHR)
:UTHR
Holding UTHR?
Track your performance easily
Earnings Data
Report Date
Feb 19, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
6.58Last Year’s EPS
4.36Same Quarter Last Year
Strong Buy
Based on 12 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Oct 31, 2018
|% Change Since: 1.74%
|Next Earnings Date:Aug 01, 2018
Earnings Call Sentiment|Positive
The earnings call was largely positive, with significant revenue growth across multiple products and the successful completion of a share repurchase program. However, there were some challenges, such as a litigation accrual and a slight decline in international Remodulin revenue.Company Guidance
During the third quarter of 2024 earnings call for United Therapeutics (UTHR), the company provided guidance emphasizing their commitment to capital allocation priorities, including investments in their clinical development pipeline, manufacturing facilities, and strategic acquisitions. The accelerated share repurchase (ASR) program with Citi, completed in September, repurchased $1 billion of UTHR stock, reducing outstanding shares by 7% and boosting stock liquidity with a 47% appreciation since March 2024. The company reported a record revenue of $749 million, marking a 23% increase from the previous year, driven by products like Tyvaso, which saw a 33% increase in revenue, and Orenitram, which grew by 23%. UTHR's robust cash flow and strong balance sheet position them to meet mid- and long-term goals, focusing on growth through innovative treatments like Tyvaso in pulmonary fibrosis and expanding their organ alternative programs. Despite a litigation accrual related to the Sandoz case, the company's outlook remains optimistic, aiming to sustain their double-digit annual revenue growth towards a $4 billion run rate by 2025.Record-Breaking Revenue and Growth
The company reported $749 million in revenue for Q3 2024, marking a 23% increase from Q3 2023. They achieved a $3 billion revenue run rate just eight quarters after surpassing the $2 billion mark.
Tyvaso Revenue Growth
Tyvaso revenue for Q3 was $434 million, a 33% increase over the previous year, driven by increased utilization and pricing.
Orenitram and Unituxin Record Revenue
Orenitram achieved $113 million in revenue, a 23% growth from the previous year, while Unituxin reached $61 million, a 19% increase.
Successful Share Repurchase Program
The company completed a $1 billion accelerated share repurchase program, repurchasing approximately 3.5 million shares.
Increased Prescriber Base
The prescriber base for Tyvaso grew by almost 15%, with 40% of new prescribers being ILD physicians, supporting market growth.
---
UTHR Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
UTHR Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Oct 30, 2024 | $352.80 | $361.40 | +2.44% |
| Jul 31, 2024 | $337.54 | $313.29 | -7.18% |
| May 01, 2024 | $234.33 | $255.14 | +8.88% |
| Feb 21, 2024 | $214.16 | $219.18 | +2.34% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does United Therapeutics Corp. (UTHR) report earnings?
United Therapeutics Corp. (UTHR) is schdueled to report earning on Feb 19, 2025, TBA Not Confirmed.
What is United Therapeutics Corp. (UTHR) earnings time?
United Therapeutics Corp. (UTHR) earnings time is at Feb 19, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is UTHR EPS forecast?
UTHR EPS forecast for the fiscal quarter 2024 (Q4) is 6.58.
---